Skip to main content

CSL CEO at Utah Life Sciences Summit

At biotech event, Paul Perreault will talk about the company’s COVID-19 response – including a potential treatment now in a clinical trial.

CSL Limited CEO Paul Perreault in front of the CSL values

CSL Limited CEO Paul Perreault will give keynote remarks at today’s Utah Life Sciences Summit, a virtual event for Utah’s life sciences community.

Known as "Silicone Slopes" because its natural surroundings, the Salt Lake City region has an emerging tech and life sciences industry that is considered the fastest growing in the U.S. The summit, held virtually this year because of the COVID-19 pandemic, draws both regional and global leaders.

Perreault, who has been leading CSL since 2013, plans to share some of the company’s key initiatives, including its multifaceted response to the COVID-19 pandemic. CSL, with more than 27,000 employees, has launched multiple projects to support both treatments and vaccines for the coronavirus. Last month, the company announced, along with the U.S. National Institutes of Health, a Phase 3 trial to investigate whether a potential treatment derived from human plasma could improve outcomes for people hospitalized with COVID-19.

The product, developed as part of the CoVIg-19 Plasma Alliance is a “hyperimmune” that aims to provide a consistent, concentrated dose of antibodies. The potential product would not be possible without the generosity of plasma donors who, after recovering from COVID-19, donated their antibodies to the effort.

Learn about the hyperimmune and other CSL projects underway related to the pandemic.

The company is supporting two vaccine efforts – something that Dr. Gregg Sylvester, Chief Medical Officer for Seqirus, discussed earlier this week on a Utah Life Sciences Summit panel about COVID-19 vaccines. Seqirus, one of the world’s leading producers of flu vaccine, is a business of CSL and has production facilities around the world. The vaccine panel also included representatives of Janssen, Pfizer and Sanofi.